At a glance
ClinicalIndex Comparison RecordPhase 1Active· 33 enrolled
Drug / intervention
GNC-035drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability，Pharmacokinetic/Pharmacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-035 in Participants With Relapsed/Refractory Hematologic Malignancy and Locally Advanced or Metastatic Solid Tumors
In Brief
A Phase 1 clinical trial evaluating GNC-035 for Hematologic Malignancies. Active but no longer recruiting, targeting 33 participants across 7 sites.
Detailed Summary
In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in patients with relapsed/refractory hematologic malignancies will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Malignancies
CountriesChina
CollaboratorsSystImmune Inc.
Timeline
Phase 1ActiveOverdue
20222023202420252026
First PostedNov 2021
Enrollment StartFeb 2022
Primary CompletionDec 2025
TodayJul 2026
First PostedNov 3, 2021
Enrollment StartFeb 9, 2022
Primary CompletionDec 1, 2025
TodayJul 1, 2026
Enrollment to primary: 3.8 yearsPosted 4.7 years ago
Interventions
GNC-035drug
Administration by intravenous infusion.